Morel, P., Buske, C., Grunenberg, A., Kastritis, E., Montes, L., Tomowiak, C., Hajek, R., Viardot, A., Tournilhac, O., Aurran, T., Bouclet, F., Zerazhi, H., Hivert, B., Weil, D. R., Guibert, S. D., Brandefors, L., García-Sanz, R., Silva, M. D., Kimby, E., Schmelzle, B., Kaszynski, D., Verlay, M., Skrzypczak, C., Dreyhaupt, J., Muche, R., Dimopoulos, M. (2025). Dexamethasone, Rituximab and Cyclophosphamide with Bortezomib is a rapidly acting and highly efficient first-line treatment in Waldenström's Macroglobulinemia: Final analysis of ECWM-1 trial of the European Consortium for Waldenström's Macroglobulinemia (ECWM). Blood. https://doi.org/10.1182/blood-2025-223